Japan’s Eisai (TYO: 4523) has outlined details of 11 presentations slated for the upcoming annual Alzheimer’s Association International Conference (AAIC), taking place from July 26 in Colorado, USA.
Likely to draw most attention is data related to the firm’s investigational anti-amyloid beta protofibril antibody, lecanemab.
Interest in the firm’s amyloid-targeting assets is at an all-time high, after the firm’s US partner Biogen (Nasdaq: BIIB) won an historic US FDA approval for the first new Alzheimer’s treatment in decades, Aduhelm (aducanumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze